News

Immunovaccine has signed a collaborative agreement with the National Cancer Institute (NCI) in Maryland, US. The research collaboration involves formulating NCI’s cancer vaccine antigens in DepoVax, Immunovaccine’s vaccine

Lubrizol has appointed Edward Campbell to its board of directors. Mr. Campbell is chairman, president and CEO of Nordson Corporation. Mr. Campbell spent 11 years in operating and

ImmuneRegen has reported positive results from a study that evaluated its lead anti-Influenza drug, Homspera. The study in animals infected with H5N1 (Avian) Influenza virus, revealed that Homspera

GlaxoSmithKline (GSK) and Genmab’s antibody Arzerra, which has been approved for use in patients with chronic lymphocytic leukemia (CLL) by the US Food and Drug Administration (FDA), will

Bio-Solutions has reported the negotiation of a supply agreement for its main product GreenEx with three African Countries. The agreement will include the turn key operation of the

Teva Pharmaceutical has reported that the US District Court for the District of Delaware has issued a decision in its litigation over the company’s Abbreviated New Drug Application

The University of Cambridge and Life Technologies have formed a collaboration to advance translational research studies in key disease areas such as cancer, diabetes and neurological disorders. Through

Aastrom Biosciences will initiate its second clinical trial for the treatment of dilated cardiomyopathy (DCM), after a positive 30-day review of Aastrom’s Investigational New Drug (IND) submission by

Dara BioSciences’s compound for Type 2 diabetes (T2D) has demonstrated superior performance to comparator drugs at the Cambridge Healthtech Institute’s Conference, ‘Targeting Diabetes with Novel Therapeutics.’ Mary Kay